Sugi Predict

Sugi Predict / Targets / IDUA

IDUA

Alpha-L-iduronidase · P35475 · IDUA on Sugi Atlas →

1,305 patent compounds predicted against IDUA, 637 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL13436936 SCHEMBL13436936 0.72 4/20
SCHEMBL18819619 SCHEMBL18819619 0.72 4/20
SCHEMBL18819621 SCHEMBL18819621 0.72 4/20
SCHEMBL18819628 SCHEMBL18819628 0.72 4/20
SCHEMBL18819632 SCHEMBL18819632 0.72 4/20
SCHEMBL18819634 SCHEMBL18819634 0.72 4/20
SCHEMBL18819636 SCHEMBL18819636 0.72 4/20
SCHEMBL18819637 SCHEMBL18819637 0.72 4/20
SCHEMBL18819649 SCHEMBL18819649 0.72 4/20
SCHEMBL18830556 SCHEMBL18830556 0.72 4/20
SCHEMBL19502545 SCHEMBL19502545 0.72 4/20
SCHEMBL19784469 SCHEMBL19784469 0.72 4/20
SCHEMBL20888690 SCHEMBL20888690 0.72 4/20
SCHEMBL23791991 SCHEMBL23791991 0.70 4/20
SCHEMBL18820163 SCHEMBL18820163 0.69 4/20
SCHEMBL18820166 SCHEMBL18820166 0.69 4/20
SCHEMBL18820167 SCHEMBL18820167 0.69 4/20
SCHEMBL18820168 SCHEMBL18820168 0.69 4/20
SCHEMBL18820169 SCHEMBL18820169 0.69 4/20
SCHEMBL18820170 SCHEMBL18820170 0.69 4/20

Clinical trials — most relevant to IDUA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease PHASE4COMPLETED
A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients PHASE4COMPLETED
A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India PHASE4COMPLETED
Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy PHASE4COMPLETED
China Post-marketing Surveillance (PMS) Study of Aldurazyme® PHASE4COMPLETED
Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I PHASE3COMPLETED
Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment PHASE2/PHASE3COMPLETED
Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II) PHASE2/PHASE3COMPLETED
Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease PHASE3COMPLETED
Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment PHASE2/PHASE3ACTIVE_NOT_RECRUITING
RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) PHASE3ACTIVE_NOT_RECRUITING
RGX-111 Gene Therapy in Patients With MPS I PHASE1/PHASE2SUSPENDED
A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old PHASE2COMPLETED
Gene Therapy With Modified Autologous Hematopoietic Stem Cells for the Treatment of Patients With Mucopolysaccharidosis Type I, Hurler Variant PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I PHASE1/PHASE2COMPLETED
Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type II PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study of Idursulfase-beta (GC1111) in Hunter Syndrome PHASE2UNKNOWN
Immune Tolerance Study With Aldurazyme® (Laronidase) PHASE1/PHASE2COMPLETED
RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome) PHASE1/PHASE2COMPLETED
A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type I PHASE1RECRUITING
A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers PHASE1COMPLETED
A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers PHASE1COMPLETED
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I nanCOMPLETED
Biomarker for Hurler Disease (BioHurler) nanWITHDRAWN
Mucopolysaccharidosis I (MPS I) Registry nanCOMPLETED
Long Term Follow-Up for RGX-111 nanENROLLING_BY_INVITATION
The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients nanUNKNOWN
Mucopolysaccharidosis Type II Observational nanWITHDRAWN
A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a IDUA binder may also engage these)

ProteinNameSimilarity
Q01634 — 1.000 Q01634 →
P48441 — 0.985 P48441 →
IL4I1 L-amino-acid oxidase 0.983 landscape →
O75064 — 0.981 O75064 →
ENGASE Cytosolic endo-beta-N-acetylglucosaminidase 0.979 landscape →
Q8IWF2 — 0.979 Q8IWF2 →
O09046 — 0.979 O09046 →
Q9Y4C4 — 0.978 Q9Y4C4 →
P0C7A1 — 0.978 P0C7A1 →
Q92791 — 0.978 Q92791 →
Q3U435 — 0.977 Q3U435 →
Q92729 — 0.977 Q92729 →
Q9WU47 — 0.977 Q9WU47 →
Q90830 — 0.976 Q90830 →
INSRR Insulin receptor-related protein 0.976 landscape →
O60512 — 0.976 O60512 →
Q9BRR3 — 0.976 Q9BRR3 →
Q5RDJ3 — 0.976 Q5RDJ3 →
MST1R Macrophage-stimulating protein receptor 0.976 landscape →
Q8N8M0 — 0.976 Q8N8M0 →
Q8IUL8 — 0.975 Q8IUL8 →
P40126 — 0.975 P40126 →
Q3U1Y4 — 0.975 Q3U1Y4 →
P14617 — 0.975 P14617 →
PIGO GPI ethanolamine phosphate transferase 3, catalytic subunit 0.975 landscape →
Q9VKJ8 — 0.975 Q9VKJ8 →
Q14147 — 0.975 Q14147 →
Q9H6W3 — 0.975 Q9H6W3 →
Q3SYT1 — 0.975 Q3SYT1 →
Q62190 — 0.975 Q62190 →